IP Library Patent Application 11884811
Patent Application
App. No. 11/884,811

Methods of Making Pharmacokinetically Improved Compounds Comprising Functional Residues or Groups and Pharmaceutical Compositions Comprising Said Compounds

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/884,811
Abstract

The present invention relates to methods of modulating the pharmacokinetic and/or pharmacodynamic properties of a compound by attaching at least one functional unit or group to the compound, thereby improving its non-specific binding characteristics and/or pharmacokinetic properties. Compounds comprising at least one functional residue are provided, as are pharmaceutical compositions comprising said compounds.

Claims (73)

1 . A method of modulating the pharmacokinetic and/or pharmacodynamic property of a compound, comprising the step of:

attaching at least one functional group to a known active compound by (a) replacing a nonessential residue; or (b) substituting a nonessential residue of the compound with the at least one function group, thereby improving the pharmacokinetic properties of the compound.

2 . The method of claim 1 , wherein said at least one functional group is selected from a hydrophobic group, an ether, an oligo(ethylene glycol) group or a derivative thereof, an amine, an ammonium salt, a simple amid; an amide based on amino acids, a crown ether, a sugar, or a nitrile, an amine group, an oxalamide, a sarcosine residue, a sarcosine derivative or a sarcosine oligomer.

3 . The method of claim 2 , wherein said functional group is a sarcosine residue or sarcosine derivative.

4 . The method of claim 1 , wherein said pharmacokinetic property is reduced non-specific protein binding.

5 . A method of modulating the pharmacokinetic and/or pharmacodynamic properties of a compound, comprising: attaching a residue from the group consisting of a hydrophobic group, an ether, an oligo (ethylene glycol) group or a derivative thereof, an amine, an ammonium salt, a simple amide, an amide based on amino acids, a crown ether, a sugar, or a nitrile, an amine group, an oxalamide, a sarcosine residue, a sarcosine derivative or a sarcosine oligomer to a known active compound to generate a second compound.

6 . The method of any one of claims 1 to 5 , wherein said active compound is Vardenafil.

7 . The method of any one of claims 1 to 5 , wherein said modulated compound has the following formula:

or pharmaceutically acceptable salt, stereoisomer, or hydrate thereof, wherein

R 1 is lower alkyl;

R 2 and R 3 are independently selected from lower alkyl, and lower alkenyl and lower alkynyl, wherein the lower alkyl, lower alkenyl, and lower alkynyl may be optionally substituted with one or more halogen, lower alkoxy, hydroxy, CN, NO 2 , amino, acylamino, amido, carbonyl, and alkylthio;

A is N or C—H;

B is N, C—H, C—(SO 2 —R 4 ), or C—CO—R 4 ;

D is N, C—H, C—(SO 2 —R 4 ) or C—CO—R 4 ;

E is N or C—H;

wherein only one of A, B or E may be N, and one of B or D is C—(SO 2 —R 4 ) or C—CO—R 4 ;

R 4 is a group having the formula:

in which each R 5 , R 6 , R 7 and R 8 are independently selected from H and lower alkyl, wherein the lower alkyl may be optionally substituted with one or more halogen, lower alkoxy, hydroxy, CN, NO 2 , amino, acylamino, amido, carbonyl, and alkylthio; and additionally or alternatively R 6 and R 5 together form a 5- or 6-membered ring, or R 6 and R 7 together form a 3 to 6 membered ring; R 9 is independently selected from H and lower alkyl, wherein the lower alkyl may be optionally substituted with one or more halogen, lower alkoxy, hydroxy, CN, NO 2 , amino, acylamino, amido, carbonyl, and alkylthio; alternatively R 8 and R 9 together with the nitrogen to which they are attached form a 5- or 6-membered ring; n is to 4; and m is 1 to 6.

8 . The method of claim 7 , wherein

A is C—H;

B is C—H;

D is C—(SO 2 —R 4 ); and

E is C—H.

9 . The method of claim 8 , wherein m is 1 or 2.

10 . The method of claim 9 , wherein n is 1.

11 . The method of any one of claims 1 to 5 , wherein:

R 1 is ethyl

R 2 is methyl

R 3 is propyl

A is C—H;

B is C—H;

D is C—(SO 2 —R 4 ); and

E is C—H.

12 . The method of any one of claims 1 to 5 , wherein said modulated compound has the following formula:

wherein,

R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined in claim 6 for formula A.

13 . The method of claim 11 , wherein the modulated compound has the formula

wherein,

R 1 , R 2 and R 3 are independently selected from H and lower alkyl, wherein the lower alkyl may be optionally substituted with one or more halogen, lower alkoxy, hydroxy, CN, NO 2 , amino, acylamino, amido, carbonyl, and alkylthio.

14 . The method of claims 1 to 5 , wherein said modulated compound has the following formula:

wherein,

R 1 is lower alkyl;

R 2 and R 3 are independently selected from lower alkyl, and lower alkenyl and lower alkynyl, wherein the lower alkyl, lower alkenyl, and lower alkynyl may be optionally substituted with one or more halogen, lower alkoxy, hydroxy, CN, NO 2 , amino, acylamino, amido, carbonyl, and alkylthio;

R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are independently selected from H and lower alkyl, wherein the lower alkyl may be optionally substituted with one or more halogen, lower alkoxy, hydroxy, CN, NO 2 , amino, acylamino, amido, carbonyl, and alkylthio;

and additionally or alternatively R 6 and R 5 , or R 8 and R 10 together form a 5- or 6-membered ring, or R 6 and R 7 , or R 10 and R 11 together form a 3 to 6 membered ring; and R 9 and R 12 together with the nitrogen to which they are attached form a 5- or 6-membered ring.

15 . The method of claim 14 , wherein said modulated compound has the following formula:

wherein,

R 1 , R 2 , R 3 , R 5 , R 8 , R 9 and R 12 are as defined in claim 14 .

16 . The method of claim 15 , wherein said modulated compound has the following formula:

wherein,

R 1 is lower alkyl; and

R 2 and R 3 are independently selected from lower alkyl, and lower alkenyl and lower alkynyl, wherein the lower alkyl, lower alkenyl, and lower alkynyl may be optionally substituted with one or more halogen, lower alkoxy, hydroxy, CN, NO 2 , amino, acylamino, amido, carbonyl, and alkylthio.

17 . The method of claims 1 to 5 , wherein said modulated compound is selected from

18 . The method of any one of claims 1 - 5 , wherein said modulated compound has the following formula D:

or pharmaceutically acceptable salt, stereoisomer, or hydrate thereof, wherein:

R 1 is lower alkyl;

R 2 and R 3 are independently selected from lower alkyl, and lower alkenyl and lower alkynyl, wherein the lower alkyl, lower alkenyl, and lower alkynyl may be optionally substituted with one or more halogen, lower alkoxy, hydroxy, CN, NO 2 , amino, acylamino, amido, carbonyl, and alkylthio;

A is N or C—H;

B is N, C—H, C—(SO 2 —NH—R 13 ), or C—CO—NH—R 13 ;

D is N, C—H, C—(SO 2 —NH—R 13 ) or C—CO—NH—R 13 ;

E is N or C—H;

wherein only one of A, B or E may be N, and one of B or D is C—(SO 2 —NH—R 13 ) or C—CO—NH—R 13 ;

R 13 is lower alkyl.

19 . The method of claim 18 , wherein R 13 is methyl.

20 . The method of claim 18 , wherein R 2 and R 3 are independently selected from lower alkyl.

21 . The method of claim 18 , wherein the compound has the formula D 1 :

or pharmaceutically acceptable salt, stereoisomer, or hydrate thereof, wherein

R 1 is lower alkyl;

R 2 and R 3 are independently selected from lower alkyl, and lower alkenyl and lower alkynyl, wherein the lower alkyl, lower alkenyl, and lower alkynyl may be optionally substituted with one or more halogen, lower alkoxy, hydroxy, CN, NO 2 , amino, acylamino, amido, carbonyl, and alkylthio; and

R 13 is selected from lower alkyl.

22 . The method of claim 21 , wherein R 13 is methyl.

23 . The method of claim 21 , wherein R 2 and R 3 are independently selected from lower alkyl.

24 . The method of claim 21 , wherein the compound has the formula

Assignments (6)
ENTITY CONVERSION Recorded Sep 17, 2025
From: SURFACE LOGIX, INC.
To: SURFACE LOGIX LLC
Reel/Frame 072915/0828 →
RELEASE OF SECURITY INTEREST Recorded Oct 21, 2021
From: CORTLAND CAPITAL MARKET SERVICES LLC
To: KADMON CORPORATION, LLC
Reel/Frame 057886/0192 →
SECURITY AGREEMENT Recorded Feb 7, 2013
From: KADMON CORPORATION, LLC
To: CORTLAND CAPITAL MARKET SERVICES LLC
Reel/Frame 029777/0502 →
SECURITY AGREEMENT Recorded Nov 23, 2011
From: KADMON CORPORATION, LLC
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 027278/0787 →
SECURITY AGREEMENT Recorded Nov 29, 2010
From: SURFACE LOGIX, INC.
To: SILICON VALLEY BANK
Reel/Frame 025406/0642 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2008
From: CAMPBELL, STEWART; DUFFY, DAVID; GROGAN, MICHAEL; KATES, STEVEN; OSTUNI, EMANUELE; SCHUELLER, OLIVIER; SWEETNAM, PAUL
To: SURFACE LOGIX, INC.
Reel/Frame 020535/0165 →